JP2018021079A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018021079A5 JP2018021079A5 JP2017211499A JP2017211499A JP2018021079A5 JP 2018021079 A5 JP2018021079 A5 JP 2018021079A5 JP 2017211499 A JP2017211499 A JP 2017211499A JP 2017211499 A JP2017211499 A JP 2017211499A JP 2018021079 A5 JP2018021079 A5 JP 2018021079A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- formula
- composition according
- hydroxy
- represented
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 1-hydroxy-cyclopropyl Chemical group 0.000 claims description 38
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 claims description 34
- 208000030159 metabolic disease Diseases 0.000 claims description 27
- 239000008194 pharmaceutical composition Substances 0.000 claims description 25
- 206010061218 Inflammation Diseases 0.000 claims description 18
- 201000001421 hyperglycemia Diseases 0.000 claims description 18
- 230000004054 inflammatory process Effects 0.000 claims description 18
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 15
- 208000002177 Cataract Diseases 0.000 claims description 12
- 230000015572 biosynthetic process Effects 0.000 claims description 12
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 10
- 206010022489 Insulin Resistance Diseases 0.000 claims description 10
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 10
- 230000009885 systemic effect Effects 0.000 claims description 10
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 10
- 241000282465 Canis Species 0.000 claims description 9
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims description 9
- 206010020772 Hypertension Diseases 0.000 claims description 9
- 208000001280 Prediabetic State Diseases 0.000 claims description 9
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 9
- 230000008085 renal dysfunction Effects 0.000 claims description 9
- 230000001668 ameliorated effect Effects 0.000 claims description 8
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 6
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims description 6
- 206010023379 Ketoacidosis Diseases 0.000 claims description 6
- 208000007976 Ketosis Diseases 0.000 claims description 6
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 6
- 208000023178 Musculoskeletal disease Diseases 0.000 claims description 6
- 208000008589 Obesity Diseases 0.000 claims description 6
- 206010033645 Pancreatitis Diseases 0.000 claims description 6
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 6
- 208000010706 fatty liver disease Diseases 0.000 claims description 6
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims description 6
- 201000008980 hyperinsulinism Diseases 0.000 claims description 6
- 235000020824 obesity Nutrition 0.000 claims description 6
- 208000011580 syndromic disease Diseases 0.000 claims description 6
- 230000003111 delayed effect Effects 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 4
- 150000001555 benzenes Chemical class 0.000 claims description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 claims description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- 206010022491 Insulin resistant diabetes Diseases 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 230000037396 body weight Effects 0.000 claims description 3
- VHOFTEAWFCUTOS-TUGBYPPCSA-N canagliflozin hydrate Chemical compound O.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1 VHOFTEAWFCUTOS-TUGBYPPCSA-N 0.000 claims description 3
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 claims description 2
- PESZPPAQWQMZAM-XNBWIAOKSA-N 2-[(4-cyclopropylphenyl)methyl]-4-[(2r,3r,4s,5s,6r)-2,3,4,5-tetrahydroxy-6-(hydroxymethyl)oxan-2-yl]benzonitrile Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@]1(O)C1=CC=C(C#N)C(CC=2C=CC(=CC=2)C2CC2)=C1 PESZPPAQWQMZAM-XNBWIAOKSA-N 0.000 claims description 2
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 2
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 claims description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- XTNGUQKDFGDXSJ-ZXGKGEBGSA-N Canagliflozin Chemical compound CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1 XTNGUQKDFGDXSJ-ZXGKGEBGSA-N 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- 102000004877 Insulin Human genes 0.000 claims description 2
- 108090001061 Insulin Proteins 0.000 claims description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 2
- GSINGUMRKGRYJP-VZWAGXQNSA-N Remogliflozin Chemical compound C1=CC(OC(C)C)=CC=C1CC1=C(C)N(C(C)C)N=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 GSINGUMRKGRYJP-VZWAGXQNSA-N 0.000 claims description 2
- ZXOCGDDVNPDRIW-NHFZGCSJSA-N Tofogliflozin Chemical compound O.C1=CC(CC)=CC=C1CC1=CC=C(CO[C@@]23[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C2=C1 ZXOCGDDVNPDRIW-NHFZGCSJSA-N 0.000 claims description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 229960001713 canagliflozin Drugs 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 229960003834 dapagliflozin Drugs 0.000 claims description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 2
- 125000006125 ethylsulfonyl group Chemical group 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 2
- 229940125396 insulin Drugs 0.000 claims description 2
- 229950000991 ipragliflozin Drugs 0.000 claims description 2
- AHFWIQIYAXSLBA-RQXATKFSSA-N ipragliflozin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(F)C(CC=2SC3=CC=CC=C3C=2)=C1 AHFWIQIYAXSLBA-RQXATKFSSA-N 0.000 claims description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 claims description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 2
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 229940126844 remogliflozin Drugs 0.000 claims description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 229940126842 sergliflozin Drugs 0.000 claims description 2
- HFLCZNNDZKKXCS-OUUBHVDSSA-N sergliflozin Chemical compound C1=CC(OC)=CC=C1CC1=CC=CC=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HFLCZNNDZKKXCS-OUUBHVDSSA-N 0.000 claims description 2
- 150000003577 thiophenes Chemical class 0.000 claims description 2
- 229950006667 tofogliflozin Drugs 0.000 claims description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 229960002429 proline Drugs 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical group CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- 102000016261 Long-Acting Insulin Human genes 0.000 description 1
- 108010092217 Long-Acting Insulin Proteins 0.000 description 1
- 229940100066 Long-acting insulin Drugs 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14152327 | 2014-01-23 | ||
| EP14152327.4 | 2014-01-23 | ||
| EP14186477 | 2014-09-25 | ||
| EP14186477.7 | 2014-09-25 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016547852A Division JP6239775B2 (ja) | 2014-01-23 | 2015-01-20 | イヌ科動物における代謝障害の治療 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019199528A Division JP7022106B2 (ja) | 2014-01-23 | 2019-11-01 | イヌ科動物における代謝障害の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018021079A JP2018021079A (ja) | 2018-02-08 |
| JP2018021079A5 true JP2018021079A5 (https=) | 2018-03-22 |
Family
ID=52432796
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016547852A Active JP6239775B2 (ja) | 2014-01-23 | 2015-01-20 | イヌ科動物における代謝障害の治療 |
| JP2017211499A Pending JP2018021079A (ja) | 2014-01-23 | 2017-11-01 | イヌ科動物における代謝障害の治療 |
| JP2019199528A Active JP7022106B2 (ja) | 2014-01-23 | 2019-11-01 | イヌ科動物における代謝障害の治療 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016547852A Active JP6239775B2 (ja) | 2014-01-23 | 2015-01-20 | イヌ科動物における代謝障害の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019199528A Active JP7022106B2 (ja) | 2014-01-23 | 2019-11-01 | イヌ科動物における代謝障害の治療 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US10603300B2 (https=) |
| EP (3) | EP4234012A3 (https=) |
| JP (3) | JP6239775B2 (https=) |
| KR (3) | KR20230122169A (https=) |
| CN (3) | CN115671290A (https=) |
| AU (2) | AU2015208291B2 (https=) |
| CA (2) | CA2932674C (https=) |
| CY (1) | CY1126101T1 (https=) |
| DK (2) | DK3096765T3 (https=) |
| EA (2) | EA201891406A1 (https=) |
| ES (2) | ES2712860T3 (https=) |
| FI (1) | FI3485890T3 (https=) |
| HU (1) | HUE062714T2 (https=) |
| LT (1) | LT3485890T (https=) |
| MX (2) | MX373034B (https=) |
| PL (2) | PL3485890T3 (https=) |
| RS (1) | RS64355B1 (https=) |
| SI (1) | SI3485890T1 (https=) |
| WO (1) | WO2015110402A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2981269T3 (da) * | 2013-04-04 | 2023-10-23 | Boehringer Ingelheim Vetmedica Gmbh | Behandling af stofskifteforstyrrelser hos hestedyr |
| MX376097B (es) | 2013-12-17 | 2025-03-07 | Boehringer Ingelheim Vetmedica Gmbh | Inhibidores de sglt2 para usarse en el tratamiento o prevención de trastornos metabólicos en animales felinos. |
| CA2932674C (en) * | 2014-01-23 | 2023-01-24 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of metabolic disorders in canine animals |
| FI3721882T3 (fi) | 2014-04-01 | 2024-09-24 | Boehringer Ingelheim Vetmedica Gmbh | Aineenvaihduntahäiriöiden hoito hevoseläimissä |
| EP4403230A3 (en) | 2014-09-25 | 2025-01-08 | Boehringer Ingelheim Vetmedica GmbH | Combination treatment of sglt2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals |
| AU2016310535B2 (en) * | 2015-08-27 | 2021-08-19 | Boehringer Ingelheim Vetmedica Gmbh | Liquid pharmaceutical compositions comprising SGLT-2 inhibitors |
| KR20180078762A (ko) * | 2016-12-30 | 2018-07-10 | 한미약품 주식회사 | 다파글리플로진 l-프롤린을 포함하는 당뇨병 질환의 예방 또는 치료용 약제학적 조성물 |
| CN110141566B (zh) * | 2018-02-11 | 2022-04-19 | 清华大学深圳研究生院 | Sglt2抑制剂在调控炎症中的应用 |
| KR102167792B1 (ko) * | 2019-10-01 | 2020-10-19 | 대한민국 | 개의 고칼슘혈증 조기 예측 또는 진단용 조성물 |
| EP4064854A1 (en) | 2019-11-28 | 2022-10-05 | Boehringer Ingelheim Vetmedica GmbH | Use of sglt-2 inhibitors in the drying-off of non-human mammals |
| CN115212197A (zh) * | 2021-04-16 | 2022-10-21 | 山东威智百科药业有限公司 | 一种包含恩格列净的药物制剂及其制备方法 |
| EP4342476A4 (en) * | 2021-05-21 | 2025-05-07 | Daewoong Pharmaceutical Co., Ltd. | Pharmaceutical composition for the prevention or treatment of diabetes mellitus in animals of the family Canidae containing enavogliflozin |
| US20240269105A1 (en) * | 2021-07-28 | 2024-08-15 | Boehringer Ingelheim Vetmedica Gmbh | Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals |
| KR20230112426A (ko) * | 2022-01-20 | 2023-07-27 | 주식회사 대웅제약 | 이나보글리플로진을 포함하는 개과 동물의 비만 예방 또는 치료용 약학 조성물 |
| WO2023227492A1 (en) | 2022-05-25 | 2023-11-30 | Boehringer Ingelheim Vetmedica Gmbh | Aqueous pharmaceutical compositions comprising sglt-2 inhibitors |
| CN119968202A (zh) * | 2022-09-29 | 2025-05-09 | 株式会社大熊制药 | 用于预防或治疗心血管衰老疾病的包含依那格列净的药物组合物 |
| TW202432104A (zh) * | 2022-12-30 | 2024-08-16 | 大陸商深圳君聖泰生物技術有限公司 | 藥物組合、藥物組合物及其應用 |
| JP2026508912A (ja) | 2023-03-06 | 2026-03-13 | ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー | 液体医薬組成物、特に１種又は複数のｓｇｌｔ－２阻害剤を含む液体医薬組成物の送達のためのシステム |
| CN121175053A (zh) | 2023-05-24 | 2025-12-19 | 勃林格殷格翰动物保健有限公司 | 包含一或多种sglt-2抑制剂及替米沙坦的非人类哺乳动物中肾脏疾病和/或高血压的组合治疗和/或预防 |
Family Cites Families (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE264337T1 (de) | 1999-08-31 | 2004-04-15 | Kissei Pharmaceutical | Glucopyranosyloxypyrazol-derivate, diese enthaltende arzneimittel und zwischenprodukte zu deren herstellung |
| US6515117B2 (en) | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
| PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
| US6683056B2 (en) | 2000-03-30 | 2004-01-27 | Bristol-Myers Squibb Company | O-aryl glucoside SGLT2 inhibitors and method |
| AU2002223127A1 (en) | 2000-11-30 | 2002-06-11 | Kissei Pharmaceutical Co., Ltd. Intellectual Property | Glucopyranosyloxybenzyl benzene derivatives, medicinal compositions containing the same and intermediates in the production thereof |
| PL209375B1 (pl) | 2000-12-28 | 2011-08-31 | Kissei Pharmaceutical | Pochodne glukopiranozyloksypirazolu, kompozycja farmaceutyczna zawierająca takie pochodne i zastosowanie tych pochodnych do wytwarzania kompozycji farmaceutycznej |
| WO2002083066A2 (en) | 2001-04-11 | 2002-10-24 | Bristol-Myers Squibb Company | Amino acid complexes of c-aryl glucosides for treatment of diabetes and method |
| JP4490109B2 (ja) | 2002-03-22 | 2010-06-23 | キッセイ薬品工業株式会社 | グルコピラノシルオキシベンジルベンゼン誘導体の結晶 |
| DE10231370B4 (de) | 2002-07-11 | 2006-04-06 | Sanofi-Aventis Deutschland Gmbh | Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
| BR0317929A (pt) | 2003-01-03 | 2006-04-11 | Bristol Myers Squibb Co | métodos de produzir inibidores de sglt2 de glicosìdeo de c-arila |
| ES2567571T3 (es) | 2003-03-14 | 2016-04-25 | Astellas Pharma Inc. | Derivados de C-glucósido y sales de los mismos |
| DE10312809A1 (de) | 2003-03-21 | 2004-09-30 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pramipexol zur Reduzierung übermäßiger Nahrungsaufnahme bei Kindern |
| LT2896397T (lt) | 2003-08-01 | 2017-11-27 | Mitsubishi Tanabe Pharma Corporation | Nauji junginiai, turintys inhibitorinį aktyvumą prieš nuo natrio priklausomą gliukozės transporterį |
| US7375090B2 (en) * | 2003-08-26 | 2008-05-20 | Boehringer Ingelheim International Gmbh | Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof |
| US7371732B2 (en) * | 2003-12-22 | 2008-05-13 | Boehringer Ingelheim International Gmbh | Glucopyranosyloxy-substituted aromatic compounds, medicaments containing such compounds, their use and process for their manufacture |
| ATE557013T1 (de) * | 2004-03-16 | 2012-05-15 | Boehringer Ingelheim Int | Glucopyranosyl-substituierte benzol-derivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| US7393836B2 (en) * | 2004-07-06 | 2008-07-01 | Boehringer Ingelheim International Gmbh | D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
| EP1773800A1 (de) * | 2004-07-27 | 2007-04-18 | Boehringer Ingelheim International GmbH | D-glucopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| AR051446A1 (es) | 2004-09-23 | 2007-01-17 | Bristol Myers Squibb Co | Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2) |
| DE102004048388A1 (de) * | 2004-10-01 | 2006-04-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| CA2587639A1 (en) * | 2004-12-16 | 2006-06-22 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
| ATE445608T1 (de) * | 2005-02-23 | 2009-10-15 | Boehringer Ingelheim Int | Glucopyranosylsubstituierte ((hetero)arylethynyl- benzyl)-benzenderivative und deren verwendung als inhibitoren des natriumabhängigen glucose- cotransporters typ 2 (sglt2) |
| ATE453656T1 (de) * | 2005-04-15 | 2010-01-15 | Boehringer Ingelheim Int | Glucopyranosyl-substituierte (heteroaryloxy- benzyl)-benzen-derivate als sglt-inhibitoren |
| UA91546C2 (uk) | 2005-05-03 | 2010-08-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ |
| US7723309B2 (en) | 2005-05-03 | 2010-05-25 | Boehringer Ingelheim International Gmbh | Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
| US7772191B2 (en) * | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
| ES2346347T3 (es) * | 2005-07-27 | 2010-10-14 | Boehringer Ingelheim International Gmbh | Derivados de ((hetero)cicloalquiletinil-bencil)-benceno y su uso como inhibidores del cotransportador de glucosa dependiente de sodio (sglt). |
| CA2620566A1 (en) * | 2005-08-30 | 2007-03-08 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
| TW200745075A (en) * | 2005-09-08 | 2007-12-16 | Boehringer Ingelheim Int | Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments |
| AR056195A1 (es) * | 2005-09-15 | 2007-09-26 | Boehringer Ingelheim Int | Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos |
| WO2007077457A2 (en) | 2006-01-06 | 2007-07-12 | The Royal Veterinary College | Treatment of equine laminitis with 5-ht1b/ 1d antagonists |
| UY30082A1 (es) * | 2006-01-11 | 2007-08-31 | Boehringer Ingelheim Int | Forma cristalina de 1-(1-metiletil)-4`-((2-fluoro-4-metoxifenil)metil)-5`- metil-1h-pirazol-3`-o-b-d-glucopiranosido, un metodo para su preparacion y el uso de la misma para preparar medicamentos |
| WO2007093610A1 (en) * | 2006-02-15 | 2007-08-23 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture |
| TWI370818B (en) | 2006-04-05 | 2012-08-21 | Astellas Pharma Inc | Cocrystal of c-glycoside derivative and l-proline |
| GB0608647D0 (en) | 2006-05-02 | 2006-06-14 | Haritou Susan J A | Methods of diagnosis and treatment |
| PE20080697A1 (es) | 2006-05-03 | 2008-08-05 | Boehringer Ingelheim Int | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion |
| JP5230613B2 (ja) | 2006-05-23 | 2013-07-10 | テラコス・インコーポレイテッド | グルコース輸送体阻害剤およびその使用方法 |
| US7919598B2 (en) * | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
| US7771695B2 (en) * | 2006-07-21 | 2010-08-10 | International Business Machines Corporation | Complexes of carbon nanotubes and fullerenes with molecular-clips and use thereof |
| TWI403516B (zh) | 2006-07-27 | 2013-08-01 | Chugai Pharmaceutical Co Ltd | To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes |
| TW200817424A (en) | 2006-08-04 | 2008-04-16 | Daiichi Sankyo Co Ltd | Benzylphenyl glucopyranoside derivatives |
| CA2656847A1 (en) * | 2006-08-15 | 2008-02-21 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture |
| CA2664095A1 (en) * | 2006-09-21 | 2008-03-27 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted difluorobenzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
| TWI499414B (zh) | 2006-09-29 | 2015-09-11 | Lexicon Pharmaceuticals Inc | 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法 |
| US8283326B2 (en) * | 2006-10-27 | 2012-10-09 | Boehringer Ingelheim International Gmbh | Crystalline form of 4-(beta-D-glucopyranos-1-yl)-1-methyl-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
| US7798264B2 (en) * | 2006-11-02 | 2010-09-21 | Hutcheson Timothy L | Reconfigurable balancing robot and method for dynamically transitioning between statically stable mode and dynamically balanced mode |
| AR063569A1 (es) * | 2006-11-06 | 2009-02-04 | Boehringer Ingelheim Int | Derivados de benzil- benzonitrilo sustituidos con glucopiranosilo medicamentos que contienen a compuestos de este tipo su uso u procedimiento para su fabricacion |
| AU2007316613B2 (en) | 2006-11-09 | 2013-11-28 | Boehringer Ingelheim International Gmbh | Combination therapy with SGLT-2 inhibitors and their pharmaceutical compositions |
| UY30730A1 (es) | 2006-12-04 | 2008-07-03 | Mitsubishi Tanabe Pharma Corp | Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno |
| JP2010519273A (ja) * | 2007-02-21 | 2010-06-03 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 四置換グルコピラノシル化ベンゼン誘導体、このような化合物を含む薬物、それらの使用及びそれらの製造方法 |
| TW200904454A (en) | 2007-03-22 | 2009-02-01 | Bristol Myers Squibb Co | Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof |
| AR065809A1 (es) | 2007-03-22 | 2009-07-01 | Bristol Myers Squibb Co | Formulaciones farmaceuticas que contienen un inhibidor sglt2 |
| AU2008279424B2 (en) | 2007-07-26 | 2013-06-13 | Lexicon Pharmaceuticals, Inc. | Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors |
| FR2920045B1 (fr) | 2007-08-16 | 2010-03-12 | Valeo Systemes Thermiques | Evaporateur a nappes multiples, en particulier pour un circuit de climatisation de vehicule automobile |
| PE20090938A1 (es) * | 2007-08-16 | 2009-08-08 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo |
| UY31291A1 (es) | 2007-08-16 | 2009-03-31 | Composicion farmacéutica que comprende un derivado de pirazol-0-glucosido | |
| MX2010002695A (es) | 2007-09-10 | 2010-04-01 | Janssen Pharmaceutica Nv | Proceso para la preparacion de compuestos utiles como inhibidores de transportador de glucosa dependiente de sodio (sglt). |
| WO2009124755A1 (en) | 2008-04-08 | 2009-10-15 | European Molecular Biology Laboratory (Embl) | Compounds with novel medical uses and method of identifying such compounds |
| US8791077B2 (en) | 2008-05-22 | 2014-07-29 | Astrazeneca Ab | Method for treating hyperuricemia employing an SGLT2 inhibitor and composition containing same |
| MX2011001855A (es) * | 2008-08-22 | 2011-03-24 | Theracos Inc | Procesos para la preparacion de inhibidores de sglt2. |
| MY155418A (en) | 2008-08-28 | 2015-10-15 | Pfizer | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
| US20100167988A1 (en) | 2008-10-22 | 2010-07-01 | Auspex Pharmaceuticals, Inc. | Ethoxyphenylmethyl inhibitors of sglt2 |
| US20100167989A1 (en) | 2008-10-23 | 2010-07-01 | Auspex Pharmaceuticals, Inc. | Isopropoxyphenylmethyl inhibitors of sglt2 |
| BRPI1008560B1 (pt) * | 2009-02-13 | 2021-08-31 | Boehringer Ingelheim International Gmbh | Composição farmacêutica compreendendo um inibidor de sglt2, um inibidor de dpp-iv e opcionalmente um outro agente antidiabético e usos dos mesmos |
| AP2011005795A0 (en) * | 2009-02-13 | 2011-08-31 | Boehringer Ingelheim Int | SGLT-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia. |
| JP5758900B2 (ja) | 2009-09-30 | 2015-08-05 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | グルコピラノシル置換ベンジルベンゼン誘導体の調製方法 |
| AU2010303123B2 (en) | 2009-09-30 | 2014-02-27 | Boehringer Ingelheim International Gmbh | Method for the preparation of a crystalline form of 1-chloro-4- (Beta-D-glucopyranos-1-yl)-2-(4-((S)-tetrahydrofuran-3-yloxy)benzyl)benzene |
| BRPI0904365A2 (pt) | 2009-11-05 | 2011-11-16 | Ouro Fino Participacoes E Empreendimentos S A | associações farmacêuticas, composições farmacêuticas, medicamento e método para o tratamento de animais |
| EP2368552A1 (en) | 2010-03-25 | 2011-09-28 | Boehringer Ingelheim Vetmedica GmbH | 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(r)-amino-piperidin-1-yl]-xanthine for the treatment of a metabolic disorder of a predominantly carnivorous non-human animal |
| WO2011153712A1 (en) | 2010-06-12 | 2011-12-15 | Theracos, Inc. | Crystalline form of benzylbenzene sglt2 inhibitor |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| US20120283169A1 (en) | 2010-11-08 | 2012-11-08 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US8614195B2 (en) | 2011-04-14 | 2013-12-24 | Novartis Ag | Glycoside derivatives and uses thereof |
| BR112013031032A2 (pt) * | 2011-06-03 | 2016-11-29 | Boehringer Ingelheim Int | inibidores de sglt-2 para o tratamento de distúrbios metabólicos em pacientes tratados com agentes neurolépticos |
| US20130035298A1 (en) * | 2011-07-08 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US20150018360A1 (en) | 2011-09-13 | 2015-01-15 | Biomed Valley Discoveries, Inc. | Compositions and methods for treating metabolic disorders |
| US9192617B2 (en) * | 2012-03-20 | 2015-11-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US9145434B2 (en) | 2012-07-26 | 2015-09-29 | Boehringer Ingelheim International Gmbh | Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments |
| EP2727587A1 (en) | 2012-10-30 | 2014-05-07 | Pharnext | Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level |
| DK2981269T3 (da) * | 2013-04-04 | 2023-10-23 | Boehringer Ingelheim Vetmedica Gmbh | Behandling af stofskifteforstyrrelser hos hestedyr |
| HRP20190101T1 (hr) * | 2013-04-05 | 2019-03-08 | Boehringer Ingelheim International Gmbh | Terapeutske uporabe empagliflozina |
| MX376097B (es) * | 2013-12-17 | 2025-03-07 | Boehringer Ingelheim Vetmedica Gmbh | Inhibidores de sglt2 para usarse en el tratamiento o prevención de trastornos metabólicos en animales felinos. |
| CA2932674C (en) * | 2014-01-23 | 2023-01-24 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of metabolic disorders in canine animals |
| FI3721882T3 (fi) * | 2014-04-01 | 2024-09-24 | Boehringer Ingelheim Vetmedica Gmbh | Aineenvaihduntahäiriöiden hoito hevoseläimissä |
| EP4403230A3 (en) | 2014-09-25 | 2025-01-08 | Boehringer Ingelheim Vetmedica GmbH | Combination treatment of sglt2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals |
| AU2016310535B2 (en) | 2015-08-27 | 2021-08-19 | Boehringer Ingelheim Vetmedica Gmbh | Liquid pharmaceutical compositions comprising SGLT-2 inhibitors |
| CN111826352A (zh) * | 2019-04-22 | 2020-10-27 | 苏州方德门达新药开发有限公司 | 通用型car-t细胞、其制备及应用 |
| WO2023227492A1 (en) * | 2022-05-25 | 2023-11-30 | Boehringer Ingelheim Vetmedica Gmbh | Aqueous pharmaceutical compositions comprising sglt-2 inhibitors |
-
2015
- 2015-01-20 CA CA2932674A patent/CA2932674C/en active Active
- 2015-01-20 KR KR1020237026312A patent/KR20230122169A/ko active Pending
- 2015-01-20 CN CN202210965596.3A patent/CN115671290A/zh active Pending
- 2015-01-20 CN CN201580005117.1A patent/CN105960242A/zh active Pending
- 2015-01-20 EP EP23171761.2A patent/EP4234012A3/en active Pending
- 2015-01-20 FI FIEP18208143.0T patent/FI3485890T3/fi active
- 2015-01-20 ES ES15701502T patent/ES2712860T3/es active Active
- 2015-01-20 DK DK15701502.5T patent/DK3096765T3/en active
- 2015-01-20 KR KR1020227021377A patent/KR20220097538A/ko not_active Ceased
- 2015-01-20 KR KR1020167022868A patent/KR102414283B1/ko active Active
- 2015-01-20 US US15/113,127 patent/US10603300B2/en active Active
- 2015-01-20 EA EA201891406A patent/EA201891406A1/ru unknown
- 2015-01-20 CN CN202210965261.1A patent/CN115282284A/zh active Pending
- 2015-01-20 MX MX2016009421A patent/MX373034B/es active IP Right Grant
- 2015-01-20 HU HUE18208143A patent/HUE062714T2/hu unknown
- 2015-01-20 LT LTEP18208143.0T patent/LT3485890T/lt unknown
- 2015-01-20 AU AU2015208291A patent/AU2015208291B2/en active Active
- 2015-01-20 EP EP15701502.5A patent/EP3096765B1/en active Active
- 2015-01-20 DK DK18208143.0T patent/DK3485890T3/da active
- 2015-01-20 PL PL18208143.0T patent/PL3485890T3/pl unknown
- 2015-01-20 WO PCT/EP2015/050940 patent/WO2015110402A1/en not_active Ceased
- 2015-01-20 JP JP2016547852A patent/JP6239775B2/ja active Active
- 2015-01-20 EP EP18208143.0A patent/EP3485890B1/en not_active Revoked
- 2015-01-20 SI SI201531955T patent/SI3485890T1/sl unknown
- 2015-01-20 ES ES18208143T patent/ES2951127T3/es active Active
- 2015-01-20 PL PL15701502T patent/PL3096765T3/pl unknown
- 2015-01-20 CA CA3181411A patent/CA3181411C/en active Active
- 2015-01-20 EA EA201600535A patent/EA032558B1/ru not_active IP Right Cessation
- 2015-01-20 RS RS20230551A patent/RS64355B1/sr unknown
-
2016
- 2016-07-20 MX MX2020003920A patent/MX2020003920A/es unknown
-
2017
- 2017-11-01 JP JP2017211499A patent/JP2018021079A/ja active Pending
-
2019
- 2019-11-01 JP JP2019199528A patent/JP7022106B2/ja active Active
-
2020
- 2020-02-14 US US16/790,810 patent/US11433045B2/en active Active
- 2020-02-18 AU AU2020201168A patent/AU2020201168B2/en active Active
-
2022
- 2022-07-26 US US17/873,638 patent/US20220378737A1/en active Pending
-
2023
- 2023-07-21 CY CY20231100353T patent/CY1126101T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018021079A5 (https=) | ||
| CA2943704C (en) | Treatment of metabolic disorders in equine animals | |
| US10864225B2 (en) | Treatment of metabolic disorders in equine animals | |
| KR102414283B1 (ko) | 개과 동물에서 대사 장애의 치료 | |
| KR102539788B1 (ko) | 말과 동물의 대사 장애를 예방하기 위한 sglt2 억제제와 도파민 작용제의 병용 치료 | |
| TWI834838B (zh) | 化合物之調配物及其用途 | |
| JP2021528384A5 (https=) | ||
| CN111565716B (zh) | 使用地匹福林的方法 | |
| IL274943B2 (en) | Combination of a 4-pyrimidinsulfamide derivative with an SGLT-2 inhibitor for the treatment of endothelin-related diseases | |
| HRP20231694T1 (hr) | Sglt-2 inhibitor za uporabu u liječenju metaboličkog poremećaja kod životinja iz porodice mačaka | |
| US10723751B2 (en) | Compositions and methods for treating infectious disease | |
| CN102046180A (zh) | 用于免疫治疗的组合物和方法 | |
| NZ625592A (en) | Compositions and methods for the treatment of hepatic diseases and disorders | |
| JP2012502047A5 (https=) | ||
| KR20140076546A (ko) | 암 치료 시스템, 방법 및 제형 | |
| JP2020504129A (ja) | 非アルコール性脂肪性肝炎（ｎａｓｈ）および肝線維症のための併用療法 | |
| Tang et al. | The novel hepatoprotective mechanisms of silibinin-phospholipid complex against d-GalN/LPS-induced acute liver injury | |
| US20260027139A1 (en) | Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist | |
| JPWO2019236775A5 (https=) | ||
| CN107137417B (zh) | 一种用于治疗恶病质的药物组合物及其应用 | |
| KR20220038339A (ko) | Sglt 억제제, 예를 들어 sglt 1/2 억제제를 포함하는 치료 | |
| KR20200013719A (ko) | 레모글리플로진의 경구 약학적 제제 | |
| US9925204B2 (en) | Anti-inflammatory compounds in combination with hydrogen for the treatment of inflammation | |
| CN118765277A (zh) | 新型泊马度胺衍生物、其制备方法及用途 | |
| Williams et al. | 535 POSTER AZD2171, a highly potent, orally active VEGF signalling inhibitor, enhances the effect of fractionated radiotherapy in human lung tumour xenografts |